This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lutfallah, C. Articles by Pang, S. Search for Related Content PubMed PubMed Citation Articles by Lutfallah, C. Articles by Pang, S. Pubmed/NCBI databases OMIM Substance via MeSH Medline Plus Health Information Hormones

Newly Proposed Hormonal Criteria via Genotypic Proof for Type II 3ß-Hydroxysteroid Dehydrogenase Deficiency

Department of Pediatrics (C.L., W.W., Y.T.C., S.P.), University of Illinois at Chicago, College of Medicine, Chicago, Illinois 60612; Department of Reproductive and Developmental Sciences (J.I.M.), University of Edinburgh, Edinburgh EH3 9YL, Scotland; Children’s Medical Center of Akron (A.H.), Akron, Ohio 44308; Department of Pediatrics (B.R.), University of Chicago, Chicago, Illinois 60637; Department of Pediatrics (M.C.-M.), Winthrop University Hospital, State University of New York, Long Island, New York 11501; Children’s Hospital of Oklahoma (K.C.C.), Oklahoma City, Oklahoma 73104; Department of Pediatrics (R.D.), New York University Medical Center, New York, New York 10016

Address all correspondence and requests for reprints to: Dr. Songya Pang, Department of Pediatrics (M/C 856), University of Illinois at Chicago, College of Medicine, 840 South Wood Street, Chicago, Illinois 60611. E-mail: . spang{at}tigger.cc.uic.edu

Abstract

To define the hormonal criteria via genotypic proof for 3ß-hydroxysteroid dehydrogenase (3ß-HSD) deficiency in the adrenals and gonads, we investigated the type II 3ß-HSD genotype in 55 patients with clinical and/or hormonal presentation suggesting compromised adrenal with or without gonadal 3ß-HSD activity. Fourteen patients (11 males and 3 females) had ambiguous genitalia with or without salt wasting and with or without premature pubarche. One female neonate had salt wasting only. Twenty-five children (4 males and 21 females) had premature pubarche only. Fifteen adolescent and adult females had hirsutism with or without menstrual disorder. The type II 3ß-HSD gene, including the promoter region up to -1053 base, all exons I, II, III, IV, and exon and intron boundaries, was sequenced in all subjects. Eight patients had a proven or predictably deleterious mutation in both alleles of the type II 3ß-HSD gene, and 47 patients had no apparent mutation in the gene. ACTH-stimulated (1 h post iv bolus of 250 µg Cortrosyn) serum 17-hydroxypregnenolone (5–17P) levels and basal and ACTH-stimulated ratios of 5–17P to cortisol (F) in the genotypic proven patients were unequivocally higher than those of age-matched or pubic hair stage matched genotype-normal patients or control subjects (n = 7–30 for each group). All other baseline and ACTH-stimulated hormone parameters, including dehydroepiandrosterone (DHEA) levels, ratios of 5–17P to 17-OHP and DHEA to androstenedione in the genotype-proven patients, overlapped with the genotype-normal patients or control subjects. The hormonal findings in the genotype-proven patients suggest that the following hormonal criteria are compatible with 3ß-HSD deficiency congenital adrenal hyperplasia (numeric and graphic reference standards from infancy to adulthood are provided): ACTH-stimulated 5–17P levels in 1) neonatal infants with ambiguous genitalia at or greater than 378 nmol/liter equivalent to or greater than 5.3 SD above the control mean level [95 ± 53 (SD) nmol/liter]; 2) Tanner I children with ambiguous genitalia at or greater than 165 nmol/liter equivalent to or greater than 35 SD above the control mean level [12 ± 4.3 (SD) nmol/liter]; 3) children with premature pubarche at or greater than 294 nmol/liter equivalent to or greater than 54 SD above Tanner II pubic hair stage matched control mean level [17 ± 5 (SD) nmol/liter]; and 4) adults with at or greater than 289 nmol/liter equivalent to or greater than 21 SD above the normal mean level [25 ± 12 (SD) nmol/liter]. ACTH-stimulated ratio of 5–17P to F in 1) neonatal infants at or greater than 434 equivalent to or greater than 6.4 SD above the control mean ratio [88 ± 54 (SD)]; 2) Tanner I children at or greater than 216 equivalent to or greater than 23 SD above the control mean ratio [12 ± 9 (SD)]; 3) children with premature pubarche at or greater than 363 equivalent to or greater than 38 SD above the control mean ratio [20 ± 9 (SD)]; and 4) adults at or greater than 4010 equivalent to or greater than 221 SD above the normal mean ratio [29 ± 18 (SD)]. Conversely, the hormonal data in the genotype-normal patients suggest the following hormonal criteria are not consistent with 3ß-HSD deficiency congenital adrenal hyperplasia: ACTH-stimulated 5–17P levels in children with premature pubarche up to 72 nmol/liter equivalent to up to 11 SD above the control mean level, and in hirsute females up to 150 nmol/liter equivalent to up to 12 SD above the normal female mean level [28 ± 10 (SD) nmol/liter]; and ACTH-stimulated 5–17P to F ratio in children with premature pubarche up to 67 equivalent to up to 5 SD above the control mean ratio, and in hirsute females up to 151 equivalent to up to 10 SD above the normal mean ratio [32 ± 12 (SD)]. These findings help define newly proposed hormonal criteria to accurately predict inherited 3ß-HSD deficiency.

This article has been cited by other articles:

				L. M. Mermejo, L. L. K. Elias, S. Marui, A. C. Moreira, B. B. Mendonca, and M. de Castro Refining Hormonal Diagnosis of Type II 3{beta}-Hydroxysteroid Dehydrogenase Deficiency in Patients with Premature Pubarche and Hirsutism Based on HSD3B2 Genotyping J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1287 - 1293. [Abstract] [Full Text] [PDF]

				N. M. Holmes, W. L. Miller, and L. S. Baskin Lack of Defects in Androgen Production in Children with Hypospadias J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2811 - 2816. [Abstract] [Full Text] [PDF]

				G. Carbunaru, P. Prasad, B. Scoccia, P. Shea, N. Hopwood, F. Ziai, Y. T. Chang, S. E. Myers, J. I. Mason, and S. Pang The Hormonal Phenotype of Nonclassic 3{beta}-Hydroxysteroid Dehydrogenase (HSD3B) Deficiency in Hyperandrogenic Females Is Associated with Insulin-Resistant Polycystic Ovary Syndrome and Is Not a Variant of Inherited HSD3B2 Deficiency J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 783 - 794. [Abstract] [Full Text] [PDF]

				E. Codner, C. Okuma, G. Iniguez, M. A. Boric, A. Avila, M. C. Johnson, and F. G. Cassorla Molecular Study of the 3{beta}-Hydroxysteroid Dehydrogenase Gene Type II in Patients with Hypospadias J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 957 - 964. [Abstract] [Full Text] [PDF]